在Anonidium mannii叶片提取物中,将新陈代谢多样性与药理功效联系起来
Olusesan Ojo1, Garland K More2, Gerhard Prinsloo1
1Department of Agriculture and Animal Health, University of South Africa, Johannesburg, South Africa.
Chemistry & biodiversity
|February 25, 2026
概括
这项研究研究了Anonidium mannii叶子提取物,揭示了显著的抗菌,抗氧化和细胞毒性质. 这些发现支持传统的医疗用途,并突出了这种未被充分利用的植物的新药发现潜力.
科学领域:
- 植物化学 植物化学
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 药用植物是新疗法的重要来源.
- Anonidium mannii传统上用于各种疾病,但未得到充分利用.
- 它的药理潜力需要科学验证.
研究的目的:
- 评估A. mannii叶子提取物的药理活性.
- 用先进的分析技术识别生物活性代谢物.
- 为植物的传统应用提供科学证据.
主要方法:
- 提取采用六,,和butanol-水.
- 对抗致病细菌的抗菌活性的评估.
- 通过DPPH测定对抗氧化剂潜力的评估.
- 使用MTT测定对Vero和HepG2细胞系进行细胞毒性测试.
- 使用液体染色学-质谱学 (LC-MS) 和气体染色学-质谱学 (GC-MS) 的代谢分析.
主要成果:
- 布坦醇-水提取物显示出强大的抗菌 (MIC:0.62-5.0 mg/mL) 和抗氧化剂 (IC50:0.44 ± 0.05 μg/mL) 活性.
- 赫克桑提取物对HepG2细胞表现出显著的细胞毒性选择性 (SI: 1.99).
- LC-MS确定了黄酸和咖啡酸;GC-MS暂时确定了生物活性碳化合物和,其中许多是A. mannii. 的新奇物质.
结论:
- A. mannii 叶子提取物具有显著的抗菌,抗氧化和细胞毒性.
- 已识别的代谢物与观察到的生物活性相关.
- 这项研究证实了传统的用途,并强调了A. mannii作为药物发现的有前途来源.
相关概念视频
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:15Drug Abuse and Addiction: Pharmacological Phenomena
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
01:14Agonism and Antagonism: Quantification
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...